The popularity of peptides—compounds increasingly marketed for promoting sleep, muscle growth, and anti-aging—is on the rise, prompting scrutiny from the U.S. Food and Drug Administration (FDA). While these compounds have gained traction in both bodybuilding and wellness communities, the FDA is addressing concerns about their safety and efficacy as it reviews seven specific peptides for potential availability through licensed pharmacies.
Peptides, which are short chains of amino acids that occur naturally in the body, have been linked to various health claims, including treatments for conditions like ulcerative colitis, pain management, and insomnia. Notable peptides in the spotlight include BPC-157, TB-500, and KPV. The review follows growing commercialization and promotion by social media influencers, as well as support from Health Secretary Robert F. Kennedy Jr.
Despite rising consumer demand, FDA scientists highlight a lack of solid evidence from human clinical trials to support the safety and effectiveness of these peptides. Concerns about their quality and stability also persist.
Industry advocates argue for easier access through licensed pharmacies to ensure better regulation, while the composition of the FDA advisory committee involved in the review has raised questions due to potential conflicts of interest, with several members linked to peptide businesses. Although the committee’s recommendations are advisory, they are expected to influence the FDA’s final decisions.
Source link
